BEAT icon

Heartbeam

2.44 USD
-0.04
1.61%
At close Feb 6, 4:00 PM EST
After hours
2.35
-0.09
3.69%
1 day
-1.61%
5 days
7.49%
1 month
7.49%
3 months
-2.79%
6 months
4.27%
Year to date
3.83%
1 year
35.56%
5 years
-47.97%
10 years
-47.97%
 

About: HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.

Employees: 20

0
Funds holding %
of 6,831 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

100% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 3

7% more funds holding

Funds holding: 30 [Q2] → 32 (+2) [Q3]

1.2% more ownership

Funds ownership: 8.63% [Q2] → 9.83% (+1.2%) [Q3]

4% more capital invested

Capital invested by funds: $5.84M [Q2] → $6.05M (+$211K) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$8
228%
upside
Avg. target
$8
228%
upside
High target
$8
228%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Benchmark
Bill Sutherland
79% 1-year accuracy
37 / 47 met price target
228%upside
$8
Speculative Buy
Reiterated
15 Nov 2024

Financial journalist opinion

Neutral
Business Wire
1 week ago
HeartBeam Achieves Major Milestone with FDA Submission for its Groundbreaking 12-Lead ECG Synthesis Software
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Achieves Major Milestone with FDA Submission for its Groundbreaking 12-Lead ECG Synthesis Software.
HeartBeam Achieves Major Milestone with FDA Submission for its Groundbreaking 12-Lead ECG Synthesis Software
Neutral
Business Wire
1 month ago
HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference.
HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference
Neutral
Business Wire
1 month ago
HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology.
HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology
Neutral
Business Wire
2 months ago
HeartBeam Announces Positive Data from Two Studies at Prestigious American Heart Association Conference
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces Positive Data from Two Studies at Prestigious American Heart Association Conference.
HeartBeam Announces Positive Data from Two Studies at Prestigious American Heart Association Conference
Neutral
Seeking Alpha
2 months ago
HeartBeam, Inc. (BEAT) Q3 2024 Earnings Call Transcript
HeartBeam, Inc. (NASDAQ:BEAT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Rob Eno - Chief Executive Officer Branislav Vajdic - President and Founder Tim Cruickshank - Chief Financial Officer Conference Call Participants Operator Greetings, and welcome to the HeartBeam Third Quarter 2024 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.
HeartBeam, Inc. (BEAT) Q3 2024 Earnings Call Transcript
Neutral
Business Wire
2 months ago
HeartBeam Reports Third Quarter 2024 Results
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports Third Quarter 2024 Results.
HeartBeam Reports Third Quarter 2024 Results
Neutral
Business Wire
3 months ago
HeartBeam to Host Third Quarter 2024 Results Conference Call on Thursday, November 7, 2024 at 4:30 p.m. Eastern Time
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host Third Quarter 2024 Results Conference Call on Thursday, November 7, 2024 at 4:30 p.m. Eastern Time.
HeartBeam to Host Third Quarter 2024 Results Conference Call on Thursday, November 7, 2024 at 4:30 p.m. Eastern Time
Neutral
Business Wire
3 months ago
HeartBeam Named “Rising Star” at the 6th Annual Digital Health Hub Foundation Awards
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Named “Rising Star” at the 6th Annual Digital Health Hub Foundation Awards.
HeartBeam Named “Rising Star” at the 6th Annual Digital Health Hub Foundation Awards
Neutral
Business Wire
3 months ago
HeartBeam Appoints Robert Eno as Chief Executive Officer in Preparation for US Commercialization
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Appoints Robert Eno as Chief Executive Officer in Preparation for US Commercialization.
HeartBeam Appoints Robert Eno as Chief Executive Officer in Preparation for US Commercialization
Neutral
Business Wire
4 months ago
HeartBeam Appoints Dr. Lance Myers as Chief AI Scientist
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Appoints Dr. Lance Myers as Chief AI Scientist.
HeartBeam Appoints Dr. Lance Myers as Chief AI Scientist
Charts implemented using Lightweight Charts™